{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/202033","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02342769","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"TRIUMPH","allocation":"","arm_groups":[{"arm_group_label":"Dolutegravir/Abacavir/Lamivudin","arm_group_description":"Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.","arm_type":""}],"assignment":"","brief_summary":"TRIUMPH is a prospective, non-interventional observational study on the use of the fixdose combination TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and the respective monitoring measures in the practice of HIV care in Germany. The primary study objective is a descriptive report of the incidence of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ therapy in everyday routine practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of TRIUMEQ, due to death, withdrawal of consent, lost to follow-up. TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Prospective Non-Interventional observational Study of use of TRIUMEQ and corresponding monitoring measures in clinical practice in Germany","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:33:27","criteria":"Inclusion Criteria: - Documented HIV infection - Age ≥ 18 years - HLA-B*5701-negative - Decision for first initiation of TRIUMEQ therapy made by the attending physician independent of the inclusion in this observational study Exclusion Criteria: - Prior dolutegravir therapy (cf. also Capping ABC in section 3.3 Recruitment) -Participation in a clinical trial during this study","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"403","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"5a5a4c77-fc0e-5b5c-ad92-ed9dee50e19c","internal":{"content":null,"contentDigest":"97d7b894b814f1e3c53609c2d33084c0","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Documented HIV infection - Age ≥ 18 years - HLA-B*5701-negative - Decision for first initiation of TRIUMEQ therapy made by the attending physician independent of the inclusion in this observational study Exclusion Criteria: - Prior dolutegravir therapy (cf. also Capping ABC in section 3.3 Recruitment) -Participation in a clinical trial during this study","interventions":[{"arm_group_label":"Dolutegravir/Abacavir/Lamivudin","intervention_description":"Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.","intervention_name":"Dolutegravir/Abacavir/Lamivudin","intervention_type":"Drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"10/15/2018 00:00:00","links":[],"locations":[{"City":"Berlin","Latitude":"52.493094","CountryDisplay":"Germany","Longitude":"13.3968551","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10961","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Mannheim","Latitude":"49.4861656","CountryDisplay":"Germany","Longitude":"8.4702616","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"68161","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.5496772","CountryDisplay":"Germany","Longitude":"13.3643415","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"13347","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Stuttgart","Latitude":"48.7716577","CountryDisplay":"Germany","Longitude":"9.1494571","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"70197","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Dortmund","Latitude":"51.5081979","CountryDisplay":"Germany","Longitude":"7.4416173","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"44137","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Muenchen","Latitude":"48.1362105","CountryDisplay":"Germany","Longitude":"11.572893","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80331","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.5147455","CountryDisplay":"Germany","Longitude":"13.43856","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10243","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Koeln","Latitude":"50.9485731","CountryDisplay":"Germany","Longitude":"6.9629492","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"50668","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Frankfurt am Main","Latitude":"50.1109221","CountryDisplay":"Germany","Longitude":"8.6821267","Name":"GSK Investigational Site","StateDisplay":"Hessen","PostalCode":"60590","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.4950243","CountryDisplay":"Germany","Longitude":"13.3147792","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10707","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Mainz","Latitude":"49.9990416","CountryDisplay":"Germany","Longitude":"8.2746565","Name":"GSK Investigational Site","StateDisplay":"Rheinland-Pfalz","PostalCode":"55116","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.4972347","CountryDisplay":"Germany","Longitude":"13.3429021","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"10777","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Freiburg","Latitude":"48.0044582","CountryDisplay":"Germany","Longitude":"7.8374651","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"79106","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Aachen","Latitude":"50.7780476","CountryDisplay":"Germany","Longitude":"6.0887682","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"52062","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Hamburg","Latitude":"53.5580847","CountryDisplay":"Germany","Longitude":"10.011979","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20099","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Muenchen","Latitude":"48.1340355","CountryDisplay":"Germany","Longitude":"11.5571732","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80336","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.5341936","CountryDisplay":"Germany","Longitude":"13.4230065","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"10405","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Muenchen","Latitude":"48.1582691","CountryDisplay":"Germany","Longitude":"11.5786882","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"80801","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Weimar","Latitude":"50.9936113","CountryDisplay":"Germany","Longitude":"11.3203362","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"99427","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Magdeburg","Latitude":"52.0884882","CountryDisplay":"Germany","Longitude":"11.6320016","Name":"GSK Investigational Site","StateDisplay":"Sachsen-Anhalt","PostalCode":"39120","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Koeln","Latitude":"50.9346454","CountryDisplay":"Germany","Longitude":"6.9331365","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"50674","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Ulm","Latitude":"48.4365897","CountryDisplay":"Germany","Longitude":"9.9810019","Name":"GSK Investigational Site","StateDisplay":"Baden-Wuerttemberg","PostalCode":"89081","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Osnabrueck","Latitude":"52.3073196","CountryDisplay":"Germany","Longitude":"8.026685","Name":"GSK Investigational Site","StateDisplay":"Niedersachsen","PostalCode":"49090","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Berlin","Latitude":"52.5064936","CountryDisplay":"Germany","Longitude":"13.2856413","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"14057","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Chemnitz","Latitude":"50.8365233","CountryDisplay":"Germany","Longitude":"12.9239317","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"09111","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Hamburg","Latitude":"53.5510846","CountryDisplay":"Germany","Longitude":"9.9936819","Name":"GSK Investigational Site","StateDisplay":"Hamburg","PostalCode":"20246","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Koeln","Latitude":"50.934707","CountryDisplay":"Germany","Longitude":"6.9759562","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"50679","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Frankfurt","Latitude":"50.0990675","CountryDisplay":"Germany","Longitude":"8.6738622","Name":"GSK Investigational Site","StateDisplay":"Hessen","PostalCode":"60596","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Duesseldorf","Latitude":"51.2357381","CountryDisplay":"Germany","Longitude":"6.8091727","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"40237","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:37:39","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Other","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Prospective"},"official_title":"Prospective Non-Interventional observational Study of use of Triumeq® and corresponding monitoring measures in clinical practice in Germany","org_study_id":"202033","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"","primary_compl_date":"10/15/2018 00:00:00","primary_outcomes":[{"outcome_description":"Descriptive documentation of the frequency of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ in routine daily practice in Germany","outcome_measure":"Frequency of therapeutic monitoring measures in HIV-infected patients","outcome_time_frame":"up to 3 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"Descriptive characterization of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ in routine daily practice in Germany","outcome_measure":"Type of the therapeutic monitoring measures","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"Descriptive characterization of conduct and logistics of HLA-B*5701 testing in HIV-infected patients under TRIUMEQ in routine daily practice in Germany","outcome_measure":"Details on conduct and logistics of HLA-B*5701 testing","outcome_time_frame":"Baseline","outcome_safety_issue":null},{"outcome_description":"To evaluate the frequency and type of serious adverse events and drug-related adverse events in patients treated with dolutegravir","outcome_measure":"Number of participants with Serious Adverse Events and drug-related adverse events as a measure of safety and tolerability","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"Defined as viral load < 50 copies/ml","outcome_measure":"Efficacy","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"To characterise resistance profile in case of virological failure","outcome_measure":"Resistance profile","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"To evaluate the change in patient satisfaction relative to baseline in patients treated with TRIUMEQ","outcome_measure":"Patient satisfaction","outcome_time_frame":"up to 3 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reasons for selecting TRIUMEQ","outcome_time_frame":"Baseline","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Reasons for discontinuing TRIUMEQ","outcome_time_frame":"up to 3 years","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"02/19/2015 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"202033"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}